Protein Expression Global Market Report 2023 – By Protein Expression (Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cellfree Expression), By End Use (Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations), By Product (Reagents, Competent Cells, Expression vectors, Services, Instruments), By Application (Therapeutic, Industrial, Research) – Market Size, Trends, And Global Forecast 2023-2032

Drug discovery is the process of identifying biologically active compounds that possess the potential to become therapeutic agents. The drug discovery process involves different phases, from ideation to development to approval. It is used to discover a new clinical drug for treating new, existing, and previously incurable diseases. The main types of drugs in the drug discovery market are small molecule and large molecule. The small molecules are used to identify small molecules with suitable properties for development. Small molecule refers to a low molecular weight drug that can smoothly penetrate cells. The various processes in drug discovery includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The various technologies in drug discovery includes high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and other technologies. The drug discovery is applied in many therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory disease, and other therapeutic areas. The drug discovery is used by pharmaceutical companies, CROs, and other end-users. The global drug discovery market is segmented - 1) By Drug Type: Small Molecule, Large Molecule 2) By Process: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation 3) By Technology: High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies 4) By Therapeutic Area: Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas 5) By End User: Pharmaceutical Companies, CROs, Other End-Users The global drug discovery market size will grow from $85.42 billion in 2022 to $98.48 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the drug discovery is expected to grow to $158.67 billion in 2027 at a CAGR of 12.7%. Rising healthcare expenditure is expected to propel the drug discovery market going forward. Countries around the world are spending a major share of their GDP on healthcare expenses which include hospital care, physician and clinical services, other professional services, dental services, other health, residential, and personal care, home health care, nursing care facilities, and continuing care retirement communities, prescription drugs, and others. Drug discovery holds a significant part of the health expenditure, as it is required to treat diseases and prolong life. There is an increasing need for new drugs to treat new diseases. For instance, In 2020, the US National Healthcare Expenditure (NHE) grew by 9.7% to $4.1 trillion, accounting for 19.7% of the U.S. Gross Domestic Product (GDP). Therefore, rising healthcare expenditure is expected to propel the drug discovery market growth. Major players in the drug discovery market are Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Agilent Technologies Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories Inc., AstraZeneca PLC, Shimadzu Corp., Evotec SE, Boehringer Ingelheim, Inc., Novartis, Johnson & Johnson, and WIL Research Laboratories. Technological advancements are a key trend in the drug discovery market. Companies operating in the drug discovery market are coming up with various new technologies, such as AI, imaging technology, and others, to reduce the time required for drug discovery. The imaging technology enables non-invasive biological activities occurring within organisms in response to medications to be visualised, characterised, and quantified. These methods, which make use of the strengths of either probes or tissue itself, are crucial for understanding diseases and finding new treatments. For instance, in October 2020, the CU Skaggs School of Pharmacy and Pharmaceutical Sciences, part of Colorado Anschutz, a US-based medical university, announced a new drug discovery technology that includes a new robotic screening and imaging technology which cuts the screening time for new drug therapies by half and also enables rapid and cost-effective screening of hundreds of thousands of potential therapies for diseases. In October 2021, Inotiv, a US-based contract research organization that focuses on nonclinical and analytical drug discovery and development services, acquired Plato BioPharma for $15 million. Through this acquisition, Inotiv intends to execute its strategy of developing a comprehensive range of contract research services spanning the entire drug discovery and preclinical development process. Plato BioPharma is a US-based company specialising in vivo pharmacology research and drug discovery in the cardiovascular, renal, pulmonary, and hepatic therapeutic areas. North America was the largest region in the drug discovery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drug discovery market research report is one of a series of new reports from The Business Research Company that provides drug discovery market statistics, including drug discovery industry global market size, regional shares, competitors with a drug discovery market share, detailed drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. This drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins market are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The global therapeutic proteins market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics The global therapeutic proteins market size grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global therapeutic proteins is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic proteins drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic proteins drugs developed using protein engineering technologies and approved by the FDA in the past five years. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic proteins market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins market. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic proteins drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. The therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Hematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in hematology analyzers and reagents are hematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and hematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The global hematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users The global hematology analyzers and reagents market size grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of hematology analyzers and reagents is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the hematology analyzers and reagents market growth. Major players in the hematology analyzers and reagents market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. North America was the largest region in the hematology analyzers and reagents market in 2022. Western Europe was the second largest region in the hematology analyzers and reagents market report. The regions covered in the hematology analyzers and reagents analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hematology analyzers and reagents market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The hematology analyzers and reagents market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides hematology analyzers and reagents market statistics, including hematology analyzers and reagents industry global market size, regional shares, competitors with a hematology analyzers and reagents market share, detailed hematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the hematology analyzers and reagents industry. This hematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics Market Definition

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Pharmaceutical Drugs And Biologics Logistics Market Definition

The pharmaceutical drugs and biologics market consists of sales of pharmaceutical drugs and biologics logistics services by entities (organizations, sole traders and partnerships) that provide pharmaceutical drugs and biologics logistics services. Pharmaceutical drugs and biologics logistics is the logistics of pharmaceutical and biologic drugs from the manufacturer to the end-user. It includes transportation, warehousing, inventory management and other logistics functions.

In-vitro diagnostics devices and equipment is a gadget that tests human samples collected from the human body such as tissues and blood, with the goal of using the results to help with clinical diagnosis or management. The main types of in-vitro diagnostics equipment are point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices, and equipment, and immunohematology diagnostic devices, and equipment. Hematology instruments are machines that analyze blood. The hematology instruments perform blood counts, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The global in-vitro diagnostics market is segmented - 1) By Type: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables The global in-vitro diagnostics market size will grow from $95.6 billion in 2022 to $106.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global in-vitro diagnostics is expected to grow to $148.58 billion in 2027 at a CAGR of 8.7%. Demand for point-of-care diagnostic devices is increasing as they provide rapid results, are cost-effective, and have advanced diagnosis features for patients. The number of patients seeking treatments at local physician offices, retail clinics, and in-patient homes is increasing thus boosting the demand for point-of-care testing devices. Companies in this market are focusing on developing more user-friendly, reliable, and efficient point of care devices. For instance, in March 2020, Abbott launched Novel COVID-19 Test. The test will be used on the m2000 RealTime system available in hospitals and molecular labs in the U.S. Philips also launched a new handheld blood test, Handheld Minicare I-20 system used for diagnosing heart attacks in emergency departments which provide results within 10 minutes. Major companies in the in-vitro diagnostics market include Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher (Beckman Coulter Inc), Abbott Laboratories Inc., and Thermo Fisher Scientific Inc. IVD devices are being integrated with IoT and data analytics technologies to improve device efficiency and increase device security. IoT refers to a system of interconnected devices via communication technologies such as WIFI and Bluetooth for data transfer and accessing devices remotely. Data analytics refers to qualitative and quantitative techniques, used to infer actionable information from large data sets. These technologies are helping in enhancing IVD device functionality, mainly through remote monitoring, predictive maintenance for decreased downtime, and advanced data processing capabilities. North America was the largest region in the global in-vitro diagnostics market in 2022. Asia-Pacific was the second largest region in the global in-vitro diagnostics market share. The regions covered in the global in-vitro diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in-vitro diagnostics market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The in-vitro diagnostics market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The in-vitro diagnostics market research report is one of a series of new reports from The Business Research Company that provides in-vitro diagnostics market statistics, in-vitro diagnostics industry global market size, regional shares, competitors with a in-vitro diagnostics market share, detailed in-vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics industry. This in-vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The scientific research and development services are responsible for conducting original research on a systematic basis to gain new knowledge and to apply research findings or other scientific knowledge to create new or improved products or processes. The main types of scientific research and development services are social sciences and humanities services; physical, engineering, and life sciences; nanotechnology services; and biotechnology services. Nanotechnology is the near-atomic manipulation of matter to create new structures, materials, and technologies. Many fields, including medical, consumer goods, energy, materials, and manufacturing, will benefit from the technology. The different sizes of enterprises include large enterprises, small and medium enterprises, and involve various modes such as online and offline. The global scientific research and development services market is segmented - 1) By Type: Social Sciences And Humanities Services, Physical, Engineering, And Life Sciences, Nanotechnology Services, Biotechnology Services 2) By End User Size: Large Enterprise, Small and Medium Enterprise 3) By Mode: Online, Offline The global scientific research and development services market size grew from $817.06 billion in 2022 to $897.68 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of global scientific research and development service market is expected to grow from $1,254.27 billion in 2027 at a CAGR of 8.7%. The scientific research and development services market is expected to grow rapidly due to increasing lifestyle and chronic diseases. This is mainly due to unhealthy lifestyles, a growing ageing population, rising inactivity and obesity. According to the World Health Organization, chronic disease prevalence reached 57% globally in 2020. China and India together had about 193.4 million diabetic patients in 2019, and India is expected to have about 101 million diabetic patients by 2030. In the field of mental health, the World Health Organization predicts that one in every four people will be affected by a type of mental disorder such as depression, schizophrenia, or anxiety in the future. In response to this, national governments across the globe are rapidly increasing their medical research expenditure. For instance, China's medical research spending has increased and will reach $1 trillion in 2020. Therefore, increasing investment in medical research to treat chronic diseases is further driving the demand for scientific research and development services. Major companies in the scientific research and development services market include IQVIA Holdings Inc., Battelle Memorial Institute, Defense Advanced Research Projects Agency, Lawrence Livermore National Laboratory LLC, Charles River Laboratories, Inc., Frog Design, Lawrence Berkeley National Lab, Jackson Laboratory, Piramal Group, and WuXi AppTec Co., Ltd. The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the scientific research and development services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down." The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the scientific research and development services market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. 4D printing has evolved from 3D printing with the additional feature of changing the geometrical shape and mechanical properties, with time being integrated as an additional fourth dimension. One of the major drawbacks of 3D printing is that it can only take the shape in which it was originally made and is static and inanimate. With the latest development of 4D printing, objects can now be made with responsive materials with certain inherent properties that can change or transform in response to external stimuli. It has widespread applications in medical science, such as tissue regeneration in the biomedical field. For example, printed micro tissue from bio ink can undergo maturation via cellular coating to form functional tissue constructs such as engineered tissue constructs. Major biotechnology research companies using 4D bio printing technology include Poietis, Biolife4D, and Precise Bio. North America was the largest region in the scientific research and development services market share in 2022. Asia-Pacific was the second largest region in the scientific research and development services market. The regions covered in the global scientific research and development services market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the scientific research and development services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The scientific research and development services market consists of revenue earned by entities that engage in research and experimental development on a contract, consultancy, or outsourced basis. Scientific research and development services establishments undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The scientific research and development services market research report is one of a series of new reports from The Business Research Company that provides scientific research and development services market statistics, including scientific research and development services industry global market size, regional shares, competitors with a scientific research and development services market share, detailed scientific research and development services market segments, market trends and opportunities, and any further data you may need to thrive in the scientific research and development services industry. This scientific research and development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biostimulants are substances or microorganisms that enhance plant growth when applied in small amounts by increasing the nutrient absorbency rate of plants without any adverse effect on the plants. It improves plant tolerance to biotic stress while also increasing crop productivity. The chemical origin of biostimulants includes natural and biosynthetic biostimulants. Biosynthetic biostimulants are defined as the microorganisms that are applied to plants for the purpose of enhancing their abiotic stress tolerance, nutrition efficiency, and quality traits. The main active ingredients of biostimulants are humic acid, fulvic acid, amino acids, protein hydrolysates, seaweed extracts, and other active ingredients. The various applications of biostimulants are foliar, soil, seed, and other applications. The global biostimulants market is segmented - 1) By Chemical Origin: Natural, Biosynthetic Biostimulants 2) By Active Ingredient: Humic Acid, Fulvic Acid, Amino Acids, Protein Hydrolysates, Seaweed Extracts, Other Active Ingredients 3) By Application: Foliar, Soil, Seed, Other Applications The biostimulants market size will grow from $2.79 billion in 2022 to $3.01 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of biostimulants is expected to grow from $4.09 billion in 2027 at a CAGR of 8.0%. The growth of sustainable agriculture is expected to drive the growth of the biostimulant market. There is an increased focus on sustainable agriculture due to deteriorating factors such as soil degradation, water scarcity, climate change, and also the burden of producing high crop yields to meet the demand. In sustainable agriculture, the use of artificial products like fertilizers and pesticides is prohibited since it degrades soil and harms the environment. Biostimulants, on the other hand, increase the simulation power of the plants to absorb nutrients and help in handling biotic stress. For instance, the United Nations' sustainable development goals for 2030 have a special focus on sustainable agriculture. The use of biostimulants to grow crops free of pesticides and fertilizers also helps in growing crops under unusual conditions. The use of biostimulants helps grow various crops under stress conditions, supporting sustainable agriculture and thereby driving the biostimulant market. Major players in the biostimulants market are BASF, Bayer CropScience, Novozymes A/S, Koppert Biological Systems, Verdesian Life Sciences, Lallemand Plant Care, Valagro, Syngenta, West Coast Marine Bio-Processing Corp., and Italpollina S.p.A. Uncertainty about the legal framework for biostimulants is expected to hinder the biostimulant industry report. Documentation on the labelling and efficacy of biostimulants is not available, and definitions of biostimulants are different worldwide. For instance, the US and Europe lack a specific biostimulant regulatory framework. The Europe has published the new European Fertilizer Regulation (EC) No. 2019/1009 that includes a biostimulants definition and a regulatory path for registrations of such products across the EU states. Moreover, the EU regulation is expected to become effective in 2022 and new standards for processes and methods are expected to be developed in the next few years. Thus, an uncertain legal framework hinders the biostimulant industry. Companies in the biostimulant market are coming up with innovative products to meet the demand and requirements of the customers and have an edge over their competitors. Mostly, start-ups are entering the market with new products. For example, in June 2022, a Spanish provider of biostimulation and sustainable crop nutrition introduced Biimore, an innovative biostimulant globally. It is made from specific and sustainable plant fermentation process from a combination of L-a amino acids, vitamins, sugars and traces of other natural compounds that are not found in any other biostimulant on the market. It improves yield and harvest quality parameters at ultra-low doses. In addition, in September 2022, Evonik Industries, a German specialty chemicals company commenced the development of an innovative biostimulant that reduces fertilizer use by half and keeps 93% of the yields. This is expected to be launched during 2025-2027. In November 2022, J.M. Huber Corporation, a US-based chemical manufacturing company acquired Biolchim Group for an undisclosed sum. The acquisition reinforces Huber's vision of becoming the world's leading provider of sustainable, high-performance agricultural products. Biolchim Group is an Italian manufacturer of a complete range of specialty plant nutrition and biostimulants. Asia-Pacific was the largest region in the biostimulants market in 2022. North America was the second-largest region in the global biostimulants market share. The regions covered in the biostimulants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biostimulants market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biostimulants market consists of the sales of plant extract, inorganic compound, chitosan and other biopolymer, and beneficial microbe biostimulants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biostimulants market research report is one of a series of new reports from The Business Research Company that provides biostimulant market statistics, including biostimulant industry global market size, regional shares, competitors with a biostimulant market share, detailed biostimulant market segments, market trends and opportunities, and any further data you may need to thrive in the biostimulant industry. This biostimulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.